Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
J Biol Inorg Chem ; 23(7): 1139-1151, 2018 10.
Article in English | MEDLINE | ID: mdl-29982869

ABSTRACT

Age-associated deposition of amyloid-ß in cerebral blood vessels, a condition referred to as cerebral amyloid angiopathy, can contribute to stroke and dementia. This research aimed to design new radioactive technetium-99 m complexes that bind to amyloid-ß plaques that have the potential to assist in diagnosis of cerebral amyloid angiopathy using single-photon-emitted computed tomography (SPECT) imaging. Six new pyridylthiosemicarbazide ligands containing either benzofuran or styrylpyridyl functional groups that are known to selectively bind to amyloid plaques were prepared. Non-radioactive isotopes of technetium are not available so rhenium was used as a surrogate for exploratory chemistry. The new ligands were used to prepare well-defined [Re-oxo]3+ complexes where two pyridylthiosemicarbazide ligands were coordinated to a single metal ion to give bivalent complexes with two amyloid-ß targeting functional groups. The interaction of the [Re-oxo]3+ complexes with synthetic amyloid-ß1-42 and with amyloid plaques in human brain tissue was investigated. Two ligands were selected to develop methods to prepare their [99mTc-oxo]3+ complexes at the tracer level. These technetium-99 m complexes are likely to be isostructural to their rhenium-oxo analogues.


Subject(s)
Amyloid beta-Peptides/chemistry , Coordination Complexes/chemistry , Hydrazines/chemistry , Rhenium/chemistry , Technetium/chemistry , Thioamides/chemistry , Binding Sites , Brain , Coordination Complexes/chemical synthesis , Crystallography, X-Ray , Humans , Ligands , Models, Molecular , Molecular Structure
2.
Inorg Chem ; 54(19): 9556-67, 2015 Oct 05.
Article in English | MEDLINE | ID: mdl-26397162

ABSTRACT

The intracellular distribution of fluorescently labeled copper and zinc bis(thiosemicarbazonato) complexes was investigated in M17 neuroblastoma cells and primary cortical neurons with a view to providing insights into the neuroprotective activity of a copper bis(thiosemicarbazonato) complex known as Cu(II)(atsm). Time-resolved fluorescence measurements allowed the identification of the Cu(II) and Zn(II) complexes as well as the free ligand inside the cells by virtue of the distinct fluorescence lifetime of each species. Confocal fluorescent microscopy of cells treated with the fluorescent copper(II)bis(thiosemicarbazonato) complex revealed significant fluorescence associated with cytoplasmic puncta that were identified to be lysosomes in primary cortical neurons and both lipid droplets and lysosomes in M17 neuroblastoma cells. Fluorescence lifetime imaging microscopy confirmed that the fluorescence signal emanating from the lipid droplets could be attributed to the copper(II) complex but also that some degree of loss of the metal ion led to diffuse cytosolic fluorescence that could be attributed to the metal-free ligand. The accumulation of the copper(II) complex in lipid droplets could be relevant to the neuroprotective activity of Cu(II)(atsm) in models of amyotrophic lateral sclerosis and Parkinson's disease.


Subject(s)
Coordination Complexes/pharmacokinetics , Copper/chemistry , Fluorescence , Thiosemicarbazones/chemistry , Zinc/chemistry , Cell Line, Tumor , Coordination Complexes/chemical synthesis , Coordination Complexes/chemistry , Humans , Models, Molecular , Molecular Structure , Spectrometry, Fluorescence , Time Factors , Tissue Distribution
3.
Neurobiol Dis ; 81: 20-4, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25766674

ABSTRACT

Mutations in the metalloprotein Cu,Zn-superoxide dismutase (SOD1) cause approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease for which effective therapeutics do not yet exist. Transgenic rodent models based on over-expression of mutant SOD1 have been developed and these have provided opportunity to test new therapeutic strategies and to study the mechanisms of mutant SOD1 toxicity. Although the mechanisms of mutant SOD1 toxicity are yet to be fully elucidated, incorrect or incomplete metallation of SOD1 confers abnormal folding, aggregation and biochemical properties, and improving the metallation state of SOD1 provides a viable therapeutic option. The therapeutic effects of delivering copper (Cu) to mutant SOD1 have been demonstrated recently. The aim of the current study was to determine if delivery of zinc (Zn) to SOD1 was also therapeutic. To investigate this, SOD1G37R mice were treated with the metal complex diacetyl-bis(4-methylthiosemicarbazonato)zinc(II) [Zn(II)(atsm)]. Treatment resulted in an improvement in locomotor function and survival of the mice. However, biochemical analysis of spinal cord tissue collected from the mice revealed that the treatment did not increase overall Zn levels in the spinal cord nor the Zn content of SOD1. In contrast, overall levels of Cu in the spinal cord were elevated in the Zn(II)(atsm)-treated SOD1G37R mice and the Cu content of SOD1 was also elevated. Further experiments demonstrated transmetallation of Zn(II)(atsm) in the presence of Cu to form the Cu-analogue Cu(II)(atsm), indicating that the observed therapeutic effects for Zn(II)(atsm) in SOD1G37R mice may in fact be due to in vivo transmetallation and subsequent delivery of Cu.


Subject(s)
Amyotrophic Lateral Sclerosis/drug therapy , Coordination Complexes/therapeutic use , Copper/metabolism , Age Factors , Amyotrophic Lateral Sclerosis/genetics , Analysis of Variance , Animals , Disease Models, Animal , Locomotion/drug effects , Mass Spectrometry , Mice , Mice, Inbred C57BL , Mice, Transgenic , Organometallic Compounds/pharmacology , Organometallic Compounds/therapeutic use , Superoxide Dismutase/genetics , Thiosemicarbazones/pharmacology , Thiosemicarbazones/therapeutic use , Zinc/metabolism
4.
J Neurosci ; 34(23): 8021-31, 2014 Jun 04.
Article in English | MEDLINE | ID: mdl-24899723

ABSTRACT

Mutations in the metallo-protein Cu/Zn-superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS) in humans and an expression level-dependent phenotype in transgenic rodents. We show that oral treatment with the therapeutic agent diacetyl-bis(4-methylthiosemicarbazonato)copper(II) [Cu(II)(atsm)] increased the concentration of mutant SOD1 (SOD1G37R) in ALS model mice, but paradoxically improved locomotor function and survival of the mice. To determine why the mice with increased levels of mutant SOD1 had an improved phenotype, we analyzed tissues by mass spectrometry. These analyses revealed most SOD1 in the spinal cord tissue of the SOD1G37R mice was Cu deficient. Treating with Cu(II)(atsm) decreased the pool of Cu-deficient SOD1 and increased the pool of fully metallated (holo) SOD1. Tracking isotopically enriched (65)Cu(II)(atsm) confirmed the increase in holo-SOD1 involved transfer of Cu from Cu(II)(atsm) to SOD1, suggesting the improved locomotor function and survival of the Cu(II)(atsm)-treated SOD1G37R mice involved, at least in part, the ability of the compound to improve the Cu content of the mutant SOD1. This was supported by improved survival of SOD1G37R mice that expressed the human gene for the Cu uptake protein CTR1. Improving the metal content of mutant SOD1 in vivo with Cu(II)(atsm) did not decrease levels of misfolded SOD1. These outcomes indicate the metal content of SOD1 may be a greater determinant of the toxicity of the protein in mutant SOD1-associated forms of ALS than the mutations themselves. Improving the metal content of SOD1 therefore represents a valid therapeutic strategy for treating ALS caused by SOD1.


Subject(s)
Amyotrophic Lateral Sclerosis , Motor Neurons/drug effects , Mutation/genetics , Organometallic Compounds/administration & dosage , Superoxide Dismutase/genetics , Thiosemicarbazones/administration & dosage , Administration, Oral , Age Factors , Amyotrophic Lateral Sclerosis/drug therapy , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/mortality , Amyotrophic Lateral Sclerosis/pathology , Animals , Cation Transport Proteins/genetics , Chromatography, Gel , Coordination Complexes , Copper Transporter 1 , Disease Models, Animal , Humans , Locomotion/drug effects , Locomotion/genetics , Mice , Mice, Transgenic , Phenotype , Spinal Cord/drug effects , Spinal Cord/metabolism , Superoxide Dismutase/metabolism , Superoxide Dismutase-1
5.
Acta Neuropathol Commun ; 2: 25, 2014 Feb 28.
Article in English | MEDLINE | ID: mdl-24581221

ABSTRACT

BACKGROUND: Aberrant biometal metabolism is a key feature of neurodegenerative disorders including Alzheimer's and Parkinson's diseases. Metal modulating compounds are promising therapeutics for neurodegeneration, but their mechanism of action remains poorly understood. Neuronal ceroid lipofuscinoses (NCLs), caused by mutations in CLN genes, are fatal childhood neurodegenerative lysosomal storage diseases without a cure. We previously showed biometal accumulation in ovine and murine models of the CLN6 variant NCL, but the mechanism is unknown. This study extended the concept that alteration of biometal functions is involved in pathology in these disorders, and investigated molecular mechanisms underlying impaired biometal trafficking in CLN6 disease. RESULTS: We observed significant region-specific biometal accumulation and deregulation of metal trafficking pathways prior to disease onset in CLN6 affected sheep. Substantial progressive loss of the ER/Golgi-resident Zn transporter, Zip7, which colocalized with the disease-associated protein, CLN6, may contribute to the subcellular deregulation of biometal homeostasis in NCLs. Importantly, the metal-complex, ZnII(atsm), induced Zip7 upregulation, promoted Zn redistribution and restored Zn-dependent functions in primary mouse Cln6 deficient neurons and astrocytes. CONCLUSIONS: This study demonstrates the central role of the metal transporter, Zip7, in the aberrant biometal metabolism of CLN6 variants of NCL and further highlights the key contribution of deregulated biometal trafficking to the pathology of neurodegenerative diseases. Importantly, our results suggest that ZnII(atsm) may be a candidate for therapeutic trials for NCLs.


Subject(s)
Biological Transport/genetics , Cation Transport Proteins/deficiency , Metals/metabolism , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , Up-Regulation/genetics , Age Factors , Alkaline Phosphatase/metabolism , Animals , Astrocytes/enzymology , Cation Transport Proteins/genetics , Cells, Cultured , Dipeptides/pharmacology , Disease Models, Animal , Embryo, Mammalian , Homeostasis/genetics , Humans , Membrane Proteins/genetics , Mice , Mice, Transgenic , Mutation/genetics , Neurodegenerative Diseases/genetics , Sheep , Tropomyosin/pharmacology , Up-Regulation/drug effects , Zinc/pharmacology
6.
J Am Chem Soc ; 135(43): 16120-32, 2013 Oct 30.
Article in English | MEDLINE | ID: mdl-24070589

ABSTRACT

One of the pathological hallmarks of Alzheimer's disease is the presence of amyloid-ß plaques in the brain and the major constituent of these plaques is aggregated amyloid-ß peptide. New thiosemicarbazone-pyridylhydrazine based ligands that incorporate functional groups designed to bind amyloid-ß plaques have been synthesized. The new ligands form stable four coordinate complexes with a positron-emitting radioactive isotope of copper, (64)Cu. Two of the new Cu(II) complexes include a functionalized styrylpyridine group and these complexes bind to amyloid-ß plaques in samples of post-mortem human brain tissue. Strategies to increase brain uptake by functional group manipulation have led to a (64)Cu complex that effectively crosses the blood-brain barrier in wild-type mice. The new complexes described in this manuscript provide insight into strategies to deliver metal complexes to amyloid-ß plaques.


Subject(s)
Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides/chemistry , Copper/chemistry , Plaque, Amyloid/diagnostic imaging , Radiopharmaceuticals/chemistry , Animals , Chromatography, High Pressure Liquid , Copper Radioisotopes/chemistry , Crystallography, X-Ray , Dogs , Electrochemistry , Humans , Ligands , Mice , Models, Molecular , Molecular Conformation , Positron-Emission Tomography , Radiopharmaceuticals/pharmacokinetics , Spectrometry, Mass, Electrospray Ionization , Spectrophotometry, Ultraviolet , Tissue Distribution
7.
Article in English | MEDLINE | ID: mdl-23952668

ABSTRACT

Our objective was to assess the copper(II) complex of diacetylbis(4-methylthiosemicarbazone) [Cu(II)(atsm)] for its preclinical potential as a novel therapeutic for ALS. Experimental paradigms used were designed to assess Cu(II)(atsm) efficacy relative to treatment with riluzole, as a function of dose administered, and when administered post symptom onset. Mice expressing human Cu/Zn superoxide dismutase harbouring the disease-causing G37R mutation (SOD1-G37R) were used and effects of Cu(II)(atsm) determined by assessing mouse survival and locomotor function (rotarod assay). Cu(II)(atsm) improved SOD1-G37R mouse survival and locomotor function in a dose-dependent manner. The highest dose tested improved survival by 26%. Riluzole had a modest effect on mouse survival (3.3%) but it did not improve locomotor function. Cotreatment with Cu(II)(atsm) did not alter the protective activity of Cu(II)(atsm) administered on its own. Commencing treatment with Cu(II)(atsm) after the onset of symptoms was less effective than treatments that commenced before symptom onset but still significantly improved locomotor function and survival. Improved locomotor function and survival of SOD1-G37R mice supports the potential for Cu(II)(atsm) as a novel treatment option for ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/drug therapy , Amyotrophic Lateral Sclerosis/genetics , Copper/therapeutic use , Disease Models, Animal , Organometallic Compounds/therapeutic use , Superoxide Dismutase/genetics , Thiosemicarbazones/therapeutic use , Amyotrophic Lateral Sclerosis/enzymology , Animals , Coordination Complexes , Dose-Response Relationship, Drug , Female , Humans , Male , Mice , Mice, Transgenic , Random Allocation , Treatment Outcome
8.
PLoS One ; 8(3): e58644, 2013.
Article in English | MEDLINE | ID: mdl-23516525

ABSTRACT

Mutations in the CLN6 gene cause a variant late infantile form of neuronal ceroid lipofuscinosis (NCL; Batten disease). CLN6 loss leads to disease clinically characterized by vision impairment, motor and cognitive dysfunction, and seizures. Accumulating evidence suggests that alterations in metal homeostasis and cellular signaling pathways are implicated in several neurodegenerative and developmental disorders, yet little is known about their role in the NCLs. To explore the disease mechanisms of CLN6 NCL, metal concentrations and expression of proteins implicated in cellular signaling pathways were assessed in brain tissue from South Hampshire and Merino CLN6 sheep. Analyses revealed increased zinc and manganese concentrations in affected sheep brain in those regions where neuroinflammation and neurodegeneration first occur. Synaptic proteins, the metal-binding protein metallothionein, and the Akt/GSK3 and ERK/MAPK cellular signaling pathways were also altered. These results demonstrate that altered metal concentrations, synaptic protein changes, and aberrant modulation of cellular signaling pathways are characteristic features in the CLN6 ovine form of NCL.


Subject(s)
Manganese/metabolism , Membrane Proteins/genetics , Neuronal Ceroid-Lipofuscinoses/metabolism , Neuronal Ceroid-Lipofuscinoses/pathology , Signal Transduction , Synapses/metabolism , Zinc/metabolism , Animals , Brain/metabolism , Brain/pathology , Disease Models, Animal , Glycogen Synthase Kinase 3/metabolism , Metallothionein/metabolism , Mutation , Neuronal Ceroid-Lipofuscinoses/genetics , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Sheep
9.
J Biol Chem ; 286(51): 44035-44044, 2011 Dec 23.
Article in English | MEDLINE | ID: mdl-22033929

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a progressive paralyzing disease characterized by tissue oxidative damage and motor neuron degeneration. This study investigated the in vivo effect of diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)), which is an orally bioavailable, blood-brain barrier-permeable complex. In vitro the compound inhibits the action of peroxynitrite on Cu,Zn-superoxide dismutase (SOD1) and subsequent nitration of cellular proteins. Oral treatment of transgenic SOD1G93A mice with CuII(atsm) at presymptomatic and symptomatic ages was performed. The mice were examined for improvement in lifespan and motor function, as well as histological and biochemical changes to key disease markers. Systemic treatment of SOD1G93A mice significantly delayed onset of paralysis and prolonged lifespan, even when administered to symptomatic animals. Consistent with the properties of this compound, treated mice had reduced protein nitration and carbonylation, as well as increased antioxidant activity in spinal cord. Treatment also significantly preserved motor neurons and attenuated astrocyte and microglial activation in mice. Furthermore, CuII(atsm) prevented the accumulation of abnormally phosphorylated and fragmented TAR DNA-binding protein-43 (TDP-43) in spinal cord, a protein pivotal to the development of ALS. CuII(atsm) therefore represents a potential new class of neuroprotective agents targeting multiple major disease pathways of motor neurons with therapeutic potential for ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Organometallic Compounds/chemistry , Peroxynitrous Acid/metabolism , Superoxide Dismutase/genetics , Thiosemicarbazones/chemistry , Animals , Antioxidants/chemistry , Astrocytes/cytology , Coordination Complexes , Copper/chemistry , DNA-Binding Proteins/pharmacology , Disease Models, Animal , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microglia/cytology , Neurodegenerative Diseases/embryology , Neurons/metabolism , Oxidative Stress , Oxygen/chemistry , Spinal Cord/pathology , Superoxide Dismutase-1 , Transgenes
10.
Dalton Trans ; 40(6): 1338-47, 2011 Feb 14.
Article in English | MEDLINE | ID: mdl-21173986

ABSTRACT

Cognitive decline associated with Alzheimer's disease appears to be related to the hyper-phosphorylation of the protein tau as a consequence of increased activity of glycogen synthase kinase 3ß (GSK3ß), and subsequent formation of neurotoxic neurofibrillary tangles. Abberant metal ion homeostasis, particularly involving copper has been implicitly linked to the pathogenesis of the disease. Increasing intracellular copper concentrations has been found to trigger pathways that result in inhibition of GSK3ß. The syntheses and characterisation of tetradentate hybrid hydroxyquinoline-thiosemicarbazone proligands is presented. The ligands form stable complexes with Cu(II) where the copper ion is four coordinate and essentially square planar as characterised by single crystal X-ray crystallography. The reduction of the metal ion to Cu(I) has been studied by electrochemical techniques and occurs at potentials that permit intracellular reduction. The new complexes show class dependent cell membrane permeability in neuronal-like SH-SY5Y cells with subsequent increases in intracellular copper concentrations. The increased intracellular copper results in a dose-dependent inhibition (phosphorylation) of GSK3ß.


Subject(s)
Coordination Complexes/chemistry , Copper/chemistry , Glycogen Synthase Kinase 3/antagonists & inhibitors , Hydroxyquinolines/chemistry , Thiosemicarbazones/chemistry , Cell Line, Tumor , Cell Membrane Permeability , Coordination Complexes/chemical synthesis , Coordination Complexes/pharmacology , Copper/metabolism , Crystallography, X-Ray , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Humans , Ligands , Molecular Conformation , Oxidation-Reduction , Spectrophotometry, Ultraviolet
11.
J Am Chem Soc ; 130(38): 12570-1, 2008 Sep 24.
Article in English | MEDLINE | ID: mdl-18729360

ABSTRACT

A family of lipophilic, cationic Au(I) complexes of N-heterocyclic carbenes (NHCs) have been designed as new mitochondria-targeted antitumor agents that combine both selective mitochondrial accumulation and selective thioredoxin reductase inhibition properties within a single molecule. Two-step ligand exchange reactions with cysteine (Cys) and selenocysteine (Sec) occur with release of the NHC ligands. At physiological pH the rate constants for the reactions with Sec are 20- to 80-fold higher than those with Cys. The complexes are selectively toxic to two highly tumorigenic breast cancer cell lines and not to normal breast cells, and the degree of selectivity and potency are optimized by modification of the substituent on the simple imidazolium salt precursor. The lead compound is shown to accumulate in mitochondria of cancer cells, to cause cell death through a mitochondrial apoptotic pathway and to inhibit the activity of thioredoxin reductase (TrxR) but not the closely related and Se-free enzyme glutathione reductase.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Gold/chemistry , Mitochondria/metabolism , Mitochondrial Proteins/metabolism , Organometallic Compounds/chemistry , Organometallic Compounds/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacokinetics , Apoptosis/drug effects , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Cell Line, Tumor , Cysteine/metabolism , Drug Design , Drug Screening Assays, Antitumor , Gold/pharmacokinetics , Gold/pharmacology , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacokinetics , Heterocyclic Compounds/pharmacology , Humans , Methane/analogs & derivatives , Methane/chemical synthesis , Methane/chemistry , Methane/pharmacokinetics , Methane/pharmacology , Mitochondria/drug effects , Mitochondria/enzymology , Organometallic Compounds/chemical synthesis , Organometallic Compounds/pharmacokinetics , Selenocysteine/metabolism , Thioredoxin-Disulfide Reductase/antagonists & inhibitors
12.
Dalton Trans ; (30): 3708-15, 2006 Aug 14.
Article in English | MEDLINE | ID: mdl-16865184

ABSTRACT

Six linear, two-coordinate cationic Au(I) N-heterocyclic carbene complexes of the form [(R2Im)2Au]+ (R = Me 1, Me, Et 2, i-Pr 3, n-Bu 4, t-Bu 5 and Cy 6) have been prepared by the reaction of two equivalents of the appropriate dialkylimidazol-2-ylidene (R2Im) with (Me2S)AuCl in dmf. Single crystal structural studies for 1.PF6, 2.PF6), 3.Cl and 4-6.PF6 show that for all six complexes the gold(I) centres have quasi-linear C-Au-C coordination, with quasi-parallel pairs of aromatic imidazole planes, except in 5.PF6 where they are quasi-normal; in the latter, Au-C are 2.038(3), 2.033(3) A, cf. (e.g.) 2.027(2) A. Inter-cation Au...Au are close at 3.487(2), 3.525(2) A in 1PF6 and 2.PF6. The structural studies and low temperature NMR experiments provide no supportive evidence for the presence of pi back-bonding within this series of complexes. The lipophilicities of the six compounds, as estimated from the logarithm of the n-octanol-water partition coefficients (log P), varied across the series within the range -1.09 to 1.73. To investigate their potential as possible anti-mitochondrial anti-tumour agents, five of the compounds have been evaluated for their propensities to induce mitochondrial membrane permeabilization (MMP) in isolated rat liver mitochondria. At concentrations between 1-10 microM compounds 1.Br and 3-6.Cl induced dose-dependent, Ca2+-sensitive mitochondrial swelling at rates that increased with the lipophilicities of the complexes, with the most lipophilic compounds inducing the most rapid onset of swelling. The swelling was completely inhibited by cyclosporin A, the specific inhibitor of the mitochondrial permeability transition pore.


Subject(s)
Gold Compounds/chemical synthesis , Gold Compounds/pharmacology , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/pharmacology , Mitochondria, Liver/drug effects , Animals , Chemical Phenomena , Chemistry, Physical , Crystallography, X-Ray , Gold Compounds/chemistry , Heterocyclic Compounds/chemistry , In Vitro Techniques , Indicators and Reagents , Magnetic Resonance Spectroscopy , Mitochondrial Membranes/drug effects , Mitochondrial Swelling/drug effects , Models, Molecular , Permeability/drug effects , Rats , Spectrophotometry, Ultraviolet
13.
Dalton Trans ; (1): 37-43, 2005 Jan 07.
Article in English | MEDLINE | ID: mdl-15605145

ABSTRACT

A series of (pseudo)halo(1,3-di-tert-butylimidazol-2-ylidine)gold complexes [(But2Im)AuX](X = Cl, Br, I, CN, N3, NCO, SCN, SeCN, ONO2, OCOCH3, CH3) have been synthesized and characterised spectroscopically and structurally. 13C NMR chemical shifts for the carbene carbon vary widely with differing ancillary anion, correlating well with the sigma-donor ability of the latter and with the M-C(carbene) bond distance. These results reinforce the notion that N-heterocyclic carbene ligands are primarily sigma-donor ligands with little pi-acceptor ability.

SELECTION OF CITATIONS
SEARCH DETAIL
...